Keuangan Summit Therapeutics Inc. (SMMT)
NASDAQ · Healthcare · Biotechnology · Karyawan: 265 · CEO: Robert W. Duggan
- Harga
- $16,03 -1,05%
- Kapitalisasi pasar
- $12,8 M
- Nilai perusahaan
- $12,4 M
- Laporan terakhir
- Q2 '26 diajukan 2026-07-23
- Laporan berikutnya
- 2026-11-02 Estimasi EPS: -$0,28
Pendapatan (TTM)–– vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)–– vs tahun laluLaba operasional: –
Laba bersih (TTM)–– vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)–– vs tahun laluCapex: –
EPS dilusian (TTM)–– vs tahun laluJumlah 4 kuartal terakhir
Kas neto$670 jt+212,5% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $12,8 M EV $12,4 M
- Pendapatan
- – 12 bulan terakhir
- Pertumbuhan pendapatan
- – Konsensus FY2026
- Margin laba
- – Laba bersih / pendapatan, TTM
- P/E
- -14,3× Forward -13,8× (FY2026)
- P/S
- 0,0× Harga / penjualan, TTM
- EV / EBITDA
- -14,5× TTM
- Arus kas bebas
- – 12 bulan terakhir
- Laba bersih
- – 12 bulan terakhir
- Estimasi pendapatan
- $3,66 jt Konsensus FY2026
- Laba
- 2026-11-02 Estimasi pendapatan: $72,1 rb
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-07-23): pendapatan n/a, EPS meleset 2,0%Pendapatan – vs $114 rb yang diharapkan (–); EPS -$0,28 vs -$0,27 (-2,0%).
- Jumlah saham dilusian naik dalam setahun: 4,8%Saham dilusian pada Q2 '26: 778 jt, setahun sebelumnya: 743 jt.
- Kas neto: $670 jtKas + investasi jangka pendek: $691 jt, utang termasuk sewa: $20,4 jt; tahun lalu kas neto: $214 jt.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $0 | $0 | – |
| Laba operasional | -$220 jt | -$414 jt | +46,8% |
| Laba bersih | -$216 jt | -$412 jt | +47,7% |
| EPS dilusian | -$0,28 | -$0,56 | +50,0% |
| Arus kas operasional | -$168 jt | -$49 jt | -242,6% |
| Capex | $968 rb | $0 | – |
| Arus kas bebas | -$169 jt | -$49 jt | -244,6% |
| R&D | $158 jt | $152 jt | +4,1% |
| Kompensasi berbasis saham | $86,3 jt | $351 jt | -75,4% |
Dilaporkan vs konsensus
2026-07-23| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| EPS (basis konsensus) | -$0,28 | -$0,27 | -2,0% |
Dari laporan 2026-07-23 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q4 '22 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| License and Service | $3,97 jt | +1.482,9% | 100,0% | $4,68 jt | +158,6% |
Pendapatan per wilayah
porsi dari total| Segmen | Q4 '22 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Latin America | $220 rb | -83,2% | 100,0% | $956 rb | -45,2% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas bebas
- –
- Dikembalikan ke pemegang saham / FCF
- –
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -14,3× | – | – |
| EV / EBITDA | -14,5× | – | – |
| EV / Penjualan | 0,0× | 892,7× 2 dari 5 tahun | 147,2× – 1.638,1× |
| Harga / FCF | -31,4× | – | – |
| Harga / Nilai buku | 19,8× | 21,2× | 4,0× – 41,0× |
| Imbal hasil FCF | -3,2% | -6,5% | -21,8% – -0,9% |
| Imbal hasil modal yang diinvestasikan | -134,1% | -141,5% | -326,0% – -11,3% |
| Imbal hasil ekuitas | -204,3% | -246,3% | -784,6% – -56,9% |
Analis
Target konsensus $31,00 (+93,4%)
rentang $20,00 – $41,00 · peringkat Buy
Beli kuat0
Beli15
Tahan8
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $3,66 jt | – | -$1,16 | +19,4% | -13,8× | 9 |
| FY2027 | $59,5 jt | +1.528,4% | -$1,13 | +2,4% | -14,2× | 8 |
| FY2028 | $581 jt | +876,5% | -$0,69 | +39,0% | -23,2× | 7 |
| FY2029 | $1,7 M | +193,2% | $0,09 | +112,7% | 182,1× | 2 |
| FY2030 | $3,83 M | +124,9% | $1,57 | +1.681,7% | 10,2× | 4 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 168 angka yang ditandai Summit Therapeutics Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $22,9 jt | $23 jt | -0,4% | $20,3 jt | $4,64 jt | +337,7% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $2,97 jt | $1,02 jt | +190,2% | $7,01 jt | $2,58 jt | +172,0% |
| Accrued Liabilities, Current | $65,1 jt | $26,1 jt | +148,8% | $32,1 jt | $19,6 jt | +64,2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$2,67 jt | -$2,75 jt | +3,2% | -$2,54 jt | -$2,29 jt | -11,2% |
| Additional Paid in Capital | $3,32 M | $2,1 M | +58,4% | $2,95 M | $1,6 M | +84,4% |
| Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $3,46 jt | – | – | $619 rb2023-12-31 | $111 rb | +457,7% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 213 rb | 43,5 jt | -99,5% | 116 jt | 73,6 jt | +57,1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $68,7 jt | $479 jt | -85,6% | $732 jt | $51 jt | +1.336,7% |
| Assets | $752 jt | $324 jt | +132,1% | $751 jt | $436 jt | +72,5% |
| Assets, Current | $721 jt | $309 jt | +133,0% | $720 jt | $424 jt | +70,0% |
| Capital Expenditures Incurred but Not yet Paid | -$746 rb | $72 rb | -1.136,1% | $291 rb | $0 | – |
| Cash | $84,9 jt | $4,27 jt | +1.890,6% | $16,4 jt | $16,3 jt | +0,6% |
| Cash and Cash Equivalents, at Carrying Value | $419 jt | $298 jt | +40,8% | $225 jt | $105 jt | +114,8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $420 jt | $298 jt | +40,7% | $226 jt | $105 jt | +114,5% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $313 jt | $86,3 jt | +262,3% | $120 jt | $33,8 jt | +256,6% |
| Class of Warrant or Right, Outstanding | 0 | 0 | – | 0 | 4,63 jt | -100,0% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 1 M | 1 M | 0,0% | 1 M | 1 M | 0,0% |
| Common Stock, Shares, Issued | 793 jt | 743 jt | +6,8% | 775 jt | 738 jt | +5,1% |
| Common Stock, Shares, Outstanding | 793 jt | 743 jt | +6,8% | 775 jt | 738 jt | +5,1% |
| Common Stock, Value, Issued | $7,93 jt | $7,43 jt | +6,8% | $7,75 jt | $7,38 jt | +5,1% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$216 jt | -$566 jt | +61,9% | -$1,08 M | -$221 jt | -388,3% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current State and Local Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | $0 | – | $172 rb | $100 rb | +72,0% |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $71 rb | $0 | – | $0 | $0 | – |
| DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest | $0 | $0 | – | $0 | $0 | – |
| DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss | $606 jt | $294 jt | +106,3% | $697 jt | $396 jt | +76,0% |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterest | $606 jt | $294 jt | +106,3% | $697 jt | $396 jt | +76,0% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Gross | $134 jt2025-12-31 | $95,9 jt | +39,3% | $134 jt | $95,9 jt | +39,3% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Operating Loss Carryforwards | $73,6 jt2025-12-31 | $59,4 jt | +23,8% | $73,6 jt | $59,4 jt | +23,8% |
| Deferred Tax Assets, Other | $711 rb2025-12-31 | $475 rb | +49,7% | $711 rb | $475 rb | +49,7% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $16,1 jt2025-12-31 | $7,87 jt | +104,5% | $16,1 jt | $7,87 jt | +104,5% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $32,2 jt2025-12-31 | $14 jt | +129,7% | $32,2 jt | $14 jt | +129,7% |
| Deferred Tax Assets, Valuation Allowance | $133 jt2025-12-31 | $95,6 jt | +39,3% | $133 jt | $95,6 jt | +39,3% |
| Deferred Tax Liabilities, Gross | $417 rb2025-12-31 | $337 rb | +23,7% | $417 rb | $337 rb | +23,7% |
| Deferred Tax Liabilities, Other | $417 rb2025-12-31 | $337 rb | +23,7% | $417 rb | $337 rb | +23,7% |
| Depreciation | $46 rb | $37 rb | +24,3% | $146 rb | $89 rb | +64,0% |
| Earnings Per Share, Basic | -$0,28 | -$0,76 | +63,2% | -$1,44 | -$0,31 | -364,5% |
| Earnings Per Share, Diluted | -$0,28 | -$0,76 | +63,2% | -$1,44 | -$0,31 | -364,5% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $1 rb | $61 rb | -98,4% | $102 rb | -$18 rb | +666,7% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$227 jt | -$46,5 jt | -387,8% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21,0% | 21,0% | 0,0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $29,2 jt | $8,57 jt | +240,9% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -2,7% | -4,0% | +32,5% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $134 jt | -$130 rb | +103.202,3% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | – | – | – | -12,4% | 0,1% | -12.500,0% |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | – | – | – | $299 rb | $77 rb | +288,3% |
| Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | – | – | – | 0,0% | 0,0% | – |
| Effective Income Tax Rate Reconciliation, Percent | – | – | – | 0,0% | 0,0% | – |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | – | – | – | $0 | -$17 rb | +100,0% |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | – | – | – | 0,0% | 0,0% | – |
| Effective Income Tax Rate Reconciliation, Tax Contingency, Amount | – | – | – | $1,36 jt | $956 rb | +41,9% |
| Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | – | – | – | -0,1% | -0,4% | +75,0% |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | – | – | – | $6,83 jt | $4,78 jt | +42,8% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02